Literature DB >> 12666103

Imaging end points for monitoring neuroprotection in Parkinson's disease.

David J Brooks1.   

Abstract

In this review, the potential role of positron emission tomography and single-photon emission computed tomography as biological markers for following the progression of Parkinson's disease (PD) is discussed, and their value for assessing the efficacy of putative neuroprotective agents in PD is considered. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective approaches to PD.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12666103     DOI： 10.1002/ana.10480

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  11 in total

Review 1.  Neuroprotection in Parkinson's disease: an elusive goal.

Authors:  William C Koller; Maria G Cersosimo
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 3.  Ropinirole: current status of the studies.

Authors:  Wolfgang H Jost
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 4.  Ropinirole, a non-ergoline dopamine agonist.

Authors:  Wolfgang H Jost; Dieter Angersbach
Journal:  CNS Drug Rev       Date:  2005

Review 5.  Neuroimaging and therapeutics in movement disorders.

Authors:  Thomas Eckert; David Eidelberg
Journal:  NeuroRx       Date:  2005-04

6.  VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.

Authors:  Ming-Kai Chen; Hiroto Kuwabara; Yun Zhou; Robert J Adams; James R Brasić; Jennifer L McGlothan; Tatyana Verina; Neal C Burton; Mohab Alexander; Anil Kumar; Dean F Wong; Tomás R Guilarte
Journal:  J Neurochem       Date:  2007-11-05       Impact factor: 5.372

7.  Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Authors:  Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

8.  Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1.

Authors:  K Van Laere; L De Ceuninck; R Dom; J Van den Eynden; H Vanbilloen; J Cleynhens; P Dupont; G Bormans; A Verbruggen; L Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-03       Impact factor: 9.236

9.  Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice.

Authors:  Heather A Boger; Lawrence D Middaugh; Kennerly S Patrick; Sammanda Ramamoorthy; Emily D Denehy; Haojie Zhu; Alejandra M Pacchioni; Ann-Charlotte Granholm; Jacqueline F McGinty
Journal:  J Neurosci       Date:  2007-08-15       Impact factor: 6.167

10.  The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.

Authors:  Mitul A Mehta; Oliver D Howes; Alice Egerton; Arsime Demjaha; Philip McGuire
Journal:  Neuroimage       Date:  2009-12-23       Impact factor: 6.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.